Baird Medical Investment Holdings Limited announced a strategic partnership with Stonewood Key Capital, a New Zealand‑based investment management firm, on January 26 2026. The deal will see Stonewood Key Capital provide capital and operational support to expand Baird Medical’s manufacturing footprint and streamline logistics for its microwave ablation (MWA) systems and single‑use needles.
The partnership is designed to leverage the Hainan Free Trade Port, which began full operation on December 18 2025 and offers zero tariffs, low tax rates, and simplified customs procedures. By positioning production and distribution hubs near the port, Baird Medical aims to reduce lead times, improve cash conversion, and enhance distribution efficiency across key markets in China, the United States, and other emerging economies.
Baird Medical’s MWA technology is minimally invasive, delivering faster recovery and lower scarring compared with traditional surgery. The company is the market leader in China for thyroid MWA devices and has recently secured regulatory approvals in Pakistan, Vietnam, and the United States, while also establishing a U.S. manufacturing base and entering the Egyptian market. The partnership will accelerate the commercialization of this technology worldwide and help the company address its receivables and cash‑flow challenges amid competitive pressure from Medtronic, Johnson & Johnson, and AngioDynamics.
Financially, Baird Medical reported $37 million in revenue for Q4 2024, a 17.7% year‑over‑year increase. The company’s total shareholder equity stands at $35.6 million, with total debt of $22.4 million, resulting in a debt‑to‑equity ratio of 62.8%. The partnership is expected to provide the capital needed for further expansion while improving operational leverage and cash flow stability.
The global MWA market is projected to grow at a compound annual growth rate of 14.2% to reach $962 million by 2030, underscoring the strategic importance of accelerating Baird Medical’s market penetration. Management emphasized that the partnership “represents an extension of our global vision rather than a mere geographic expansion,” highlighting the company’s focus on patient outcomes and clinical excellence worldwide.
The collaboration signals Baird Medical’s intent to strengthen its global commercial infrastructure and position its products for broader adoption in international hospitals and clinics, while also addressing the capital‑intensive nature of its expansion strategy. The partnership is a material event that could materially alter Baird Medical’s financial trajectory and competitive positioning.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.